Loading...
•
Jun 30, 2021
Baxter Q2 2021 Earnings Report
Reported a 14% increase in worldwide sales, driven by growth across all geographic segments and product categories.
Key Takeaways
Baxter International Inc. reported strong second-quarter results, with a 14% increase in worldwide sales to $3.1 billion. U.S. GAAP EPS increased 23% to $0.59, and adjusted EPS increased 25% to $0.80. The company has raised its full-year sales growth expectations to approximately 8% and adjusted EPS to a range of $3.49 to $3.55.
Second-quarter revenue reached $3.1 billion, a 14% increase on a reported basis.
U.S. GAAP earnings per share (EPS) increased 23% to $0.59.
Adjusted EPS rose 25% to $0.80, exceeding previous guidance.
Full-year 2021 sales growth is expected to be approximately 8%.
Baxter
Baxter
Baxter Revenue by Segment
Baxter Revenue by Geographic Location
Revenue by Segment
Pharmaceuticals Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Baxter expects full-year 2021 sales growth of approximately 8% on a reported basis and U.S. GAAP earnings of $2.82 to $2.88 per diluted share and adjusted earnings of $3.49 to $3.55 per diluted share.
Positive Outlook
- Full-year 2021 sales growth of approximately 8% on a reported basis
- Full-year 2021 sales growth of 5% to 6% on a constant currency basis
- Full-year 2021 sales growth of 4% to 5% on an operational basis
- Full-year U.S. GAAP EPS of $2.82 to $2.88
- Full-year adjusted EPS of $3.49 to $3.55
Challenges Ahead
- Third-quarter sales growth of approximately 9% on a reported basis
- Third-quarter sales growth of approximately 7% on a constant currency basis
- Third-quarter sales growth of approximately 6% on an operational basis
- Third-quarter U.S. GAAP earnings of $0.79 to $0.81 per diluted share
- Third-quarter adjusted earnings of $0.93 to $0.95 per diluted share
Revenue & Expenses
Visualization of income flow from segment revenue to net income